New Q&As on Chapter 4 and 5 of the EU-GDP Guidelines
Recommendation

8 September 2026
Basel, Switzerland
Specifics in the Distribution of Medicinal Products
On the GDP Association Website a section was set up a while ago dealing with frequently asked questions (FAQs). Now a set of new FAQs has been published on Chapter 4 (Documentation) and Chapter 5 (Operations).
For example, the following questions are discussed:
- Who authors documents? Who needs to approve them?
- In which language should documents be written?
- Is it allowed to print procedures from an electronic system?
- How can I check if a supplier has an appropriate legal authorisation?
- Besides temperature, are there other environmental factors which might harm medicinal products?
- Why do I need to qualify customers?
Answers to these and other questions are provided in the new FAQs on GDP.
Related GMP News
14.07.2026USP Proposes to Revise the Definition of Controlled Room Temperature in Chapter <659>
14.07.2026GDP in Hong Kong: Authority Provides Additional Information
14.07.2026GDP Inspection Responses: MHRA’s Expectations for AI Use in GxP Replies
14.07.2026FDA Warning Letter to Amazon: Unapproved New Drugs Sold via Online Marketplace
18.06.2026GDPA Participated as an Observer in the EMA GMDP-IWG Interested Parties Meeting


